The administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs), such as gefitinib, erlotinib and afatinab, is a major breakthrough in the management of advanced non-small cell lung cancer (NSCLC) [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.